Pierrick G J Fournier
Overview
Explore the profile of Pierrick G J Fournier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
827
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Trivedi T, Zheng Y, Fournier P, Murthy S, John S, Schillo S, et al.
Oncotarget
. 2017 May;
8(16):26687-26701.
PMID: 28460457
Vitamin D has pleiotropic effects on multiple tissues, including malignant tumors. Vitamin D inhibits breast cancer growth through activation of the vitamin D receptor (VDR) and via classical nuclear signaling...
12.
Fournier P, Juarez P, Jiang G, Clines G, Niewolna M, Kim H, et al.
Cancer Cell
. 2015 May;
27(6):809-21.
PMID: 25982816
Transforming growth factor-β (TGF-β) regulates the expression of genes supporting breast cancer cells in bone, but little is known about prostate cancer bone metastases and TGF-β. Our study reveals that...
13.
Juarez P, Mohammad K, Yin J, Fournier P, McKenna R, Davis H, et al.
Cancer Res
. 2012 Sep;
72(23):6247-56.
PMID: 23002206
TGF-β derived from bone fuels melanoma bone metastases by inducing tumor secretion of prometastatic factors that act on bone cells to change the skeletal microenvironment. Halofuginone is a plant alkaloid...
14.
Mohammad K, Javelaud D, Fournier P, Niewolna M, McKenna C, Peng X, et al.
Cancer Res
. 2010 Nov;
71(1):175-84.
PMID: 21084275
Melanoma often metastasizes to bone where it is exposed to high concentrations of TGF-β. Constitutive Smad signaling occurs in human melanoma. Because TGF-β promotes metastases to bone by several types...
15.
Dunn L, Mohammad K, Fournier P, McKenna C, Davis H, Niewolna M, et al.
PLoS One
. 2009 Sep;
4(9):e6896.
PMID: 19727403
Background: Most patients with advanced breast cancer develop bone metastases, which cause pain, hypercalcemia, fractures, nerve compression and paralysis. Chemotherapy causes further bone loss, and bone-specific treatments are only palliative....
16.
Fournier P, Daubine F, Lundy M, Rogers M, Ebetino F, Clezardin P
Cancer Res
. 2008 Nov;
68(21):8945-53.
PMID: 18974139
Bisphosphonates bind avidly to bone mineral and are potent inhibitors of osteoclast-mediated bone destruction. They also exhibit antitumor activity in vitro. Here, we used a mouse model of human breast...
17.
Kingsley L, Fournier P, Chirgwin J, Guise T
Mol Cancer Ther
. 2007 Oct;
6(10):2609-17.
PMID: 17938257
Metastasis is a final stage of tumor progression. Breast and prostate cancer cells preferentially metastasize to bone, wherein they cause incurable osteolytic and osteoblastic lesions. The bone matrix is rich...
18.
19.
Fournier P, Chirgwin J, Guise T
Curr Opin Rheumatol
. 2006 Jun;
18(4):396-404.
PMID: 16763461
Purpose Of Review: Bone metastases interact with the bone microenvironment. Cancer cells modulate the functions of osteoblasts and osteoclasts to induce new bone formation or bone resorption, leading to secondary...
20.
Clezardin P, Ebetino F, Fournier P
Cancer Res
. 2005 Jun;
65(12):4971-4.
PMID: 15958534
Bisphosphonates are primarily known for their ability to inhibit osteoclast-mediated bone resorption. They are an indispensable part of therapy for patients with cancers that cause osteolysis. However, there is now...